DOI: http://dx.doi.org/10.18203/issn.2455-4529.IntJResDermatol20195199

Effectiveness of a combination of anti-pigmentary products in facial post-inflammatory hyperpigmentation

Chitra S. Nayak, Saba M. M. Ansari, Vrushali Salve, Shweta Patil

Abstract


Background: Post-inflammatory hyperpigmentation (PIH), also has psychosocial implications. Hydroquinone containing preparations though effective, have unacceptable side effects. Molecules like kojic acid, arbutin, vitamins C and E, niacinamide and many others have depigmenting effect, singly or in combination. The objective of this study was to assess the effectiveness and tolerability of a cream containing a combination of niacinamide-4.0%, glycolic acid-2.0%, vitamin E acetate-0.1%, kojic acid dipalmitate-2.0%, soy isoflavones-0.5%, arbutin-2.0%, pterowhite-0.12%, licorice-40% CA-0.12%, ascorbyl glucoside-0.1% (Melaglow-Rich, Abbott Healthcare Pvt. Ltd.) in treatment of PIH. The specific objectives were to evaluate the changes in pigmentation, safety of the cream and patient opinion regarding the cream after 90 days of use.

Methods: After IEC approval, adult males and non-pregnant, non-lactating females aged upto 50 years with PIH were included. Those with endocrinopathies who received systemic steroid therapy in the preceding month were excluded. 114 participants who were enrolled in this open-label, non-comparative study, applied study medication (b.i.d) and sunscreen (SPF-30; q.d). Effectiveness was assessed by PIH severity scale, Mexameter assessment, Patients’ and Physicians’ Global Assessment Scale and clinical photographs. Adverse events were documented.

Results: Mean PIH score and mean mexameter reading for melanin and erythema in the hyperpigmented and non-hyperpigmented skin reduced by day 90 (p=0.0009, p<0.0001, p<0.001). Significant reduction in physicians’ (p=0.004) and patients’ (p=0.006) global assessment score was evident by day 90. Itching (n=1), burning (n=3) and stinging (n=3) were noted.

Conclusions: Melaglow rich cream was found to be effective and well-tolerated in the treatment of PIH.


Keywords


PIH, Mexameter, Anti-pigmentary

Full Text:

PDF

References


Halder RM, Nootheti PK. Ethnic skin disorders overview. J Am Acad Dermatol. 2003;48(6 Suppl):S143-8.

Sarkar R, Arora P, Garg KV. Cosmeceuticals for Hyperpigmentation: What is Available? J Cutan Aesthet Surg. 2013;6(1):4-11.

Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol. 2010;3(7):20-31.

Alexis AF, Sergay AB, Taylor SC. Common dermatologic disorders in skin of color: a comparative practice survey. Cutis. 2007;80(5):387-94.

Child FJ, Fuller LC, Higgins EM, Du Vivier AW. A study of the spectrum of skin disease occurring in a black population in south-east London. Br J Dermatol. 1999;141(3):512-7.

Chua-Ty G, Goh CL, Koh SL. Pattern of skin diseases at the National Skin Centre (Singapore) from 1989-1990. Int J Dermatol. 1992;31(8):555-9.

Halder RM, Grimes PE, McLaurin CI, Kress MA, Kenney JA. Incidence of common dermatoses in a predominantly black dermatologic practice. Cutis. 1983;32(4):388, 90.

Hartshorne ST. Dermatological disorders in Johannesburg, South Africa. Clin Exp Dermatol. 2003;28(6):661-5.

Nanda A, Al-Hasawi F, Alsaleh QA. A prospective survey of pediatric dermatology clinic patients in Kuwait: an analysis of 10,000 cases. Pediatr Dermatol. 1999;16(1):6-11.

Kumar Yadalla HK, Aradhya S. Post acne hyperpigmentation: A brief review. Our Dermatology Online. 2011;2(4):230-1.

Nordlund JJ, Grimes PE, Ortonne JP. The safety of hydroquinone. J Eur Acad Dermatol Venereol. 2006;20(7):781-7.

Kahn V. Effect of kojic acid on the oxidation of DL-DOPA, norepinephrine, and dopamine by mushroom tyrosinase. Pigment Cell Res. 1995;8(5):234-40.

Fartasch M, Teal J, Menon GK. Mode of action of glycolic acid on human stratum corneum: ultrastructural and functional evaluation of the epidermal barrier. Arch Dermatol Res. 1997;289(7):404-9.

Sharad J. Glycolic acid peel therapy - a current review. Clin Cosmet Investig Dermatol. 2013;6:281-8.

Augustyniak A, Erkiert-Polguj A, Rotsztejn H. Variable pulsed light treatment of melasma and post-inflammatory hyperpigmentation - a pilot study. J Cosmet Laser Ther. 2015;17(1):15-9.

Castanedo-Cazares JP, Larraga-Pinones G, Ehnis-Perez A, Fuentes-Ahumada C, Oros-Ovalle C, Smoller BR, et al. Topical niacinamide 4% and desonide 0.05% for treatment of axillary hyperpigmentation: a randomized, double-blind, placebo-controlled study. Clin Cosmet Investig Dermatol. 2013;6:29-36.

Espinal-Perez LE, Moncada B, Castanedo-Cazares JP. A double-blind randomized trial of 5% ascorbic acid vs. 4% hydroquinone in melasma. Int J Dermatol. 2004;43(8):604-7.

Fran E Cook-Boden. The Use of a Cream Containing 4% Hydroquinone, 10% Buffered Glycolic Acid, Vitamin C, Vitamin E, and Sunscreen in the Treatment of Postinflammatory Hyperpigmentation in Skin Types IV-VI. 2003; Available from: http://www.arnellcomm.com/img/p/ ICNCookPoster.pdf. Accessed on 27th July 2019

Kircik LH. Efficacy and safety of azelaic acid (AzA) gel 15% in the treatment of post-inflammatory hyperpigmentation and acne: a 16-week, baseline-controlled study. J Drugs Dermatol. 2011;10(6):586-90.

Mendoza CG, Singzon IA, Handog EB. A randomized, double-blind, placebo-controlled clinical trial on the efficacy and safety of 3% Rumex occidentalis cream versus 4% hydroquinone cream in the treatment of melasma among Filipinos. Int J Dermatol. 2014;53(11):1412-6.

Monteiro RC, Kishore BN, Bhat RM, Sukumar D, Martis J, Ganesh HK. A Comparative Study of the Efficacy of 4% Hydroquinone vs 0.75% Kojic Acid Cream in the Treatment of Facial Melasma. Indian J Dermatol. 2013;58(2):157.

Callender VD, Young CM, Kindred C, Taylor SC. Efficacy and Safety of Clindamycin Phosphate 1.2% and Tretinoin 0.025% Gel for the Treatment of Acne and Acne-induced Post-inflammatory Hyperpigmentation in Patients with Skin of Color. J Clin Aesthet Dermatol. 2012;5(7):25-32.

Dobos G, Trojahn C, Lichterfeld A, D Alessandro B, Patwardhan SV, Canfield D, et al. Quantifying dyspigmentation in facial skin ageing: an explorative study. Int J Cosmet Sci. 2015;37(5):542-9.

Qian CY, Yuan C, Tan YM, Liu XP, Dong YQ, Yang LJ, et al. Comparing performance of Chromameter((R)) , Mexameter((R)) and full-field laser perfusion imaging for measurement of ultraviolet B light-induced erythema. Clin Exp Dermatol. 2015;40(4):438-40.

Matias AR, Ferreira M, Costa P, Neto P. Skin colour, skin redness and melanin biometric measurements: comparison study between Antera 3D, Mexameter and Colorimeter. Skin Res Technol. 2015;21(3):346-62.

Baquie M, Kasraee B. Discrimination between cutaneous pigmentation and erythema: comparison of the skin colorimeters Dermacatch and Mexameter. Skin Res Technol. 2014;20(2):218-27.

Khan BA, Akhtar N, Hussain I, Abbas KA, Rasul A. Whitening efficacy of plant extracts including Hippophae rhamnoides and Cassia fistula extracts on the skin of Asian patients with melasma. Postepy Dermatol Alergol. 2013;30(4):226-32.

Diffey BL, Oliver RJ, Farr PM. A portable instrument for quantifying erythema induced by ultraviolet radiation. Br J Dermatol. 1984;111(6):663-72.

Pandya A, Berneburg M, Ortonne JP, Picardo M. Guidelines for clinical trials in melasma. Pigmentation Disorders Academy. Br J Dermatol. 2006;156(1):21-8.

Leyden J, Wortzman M, Baldwin EK. Tolerability of clindamycin/tretinoin gel vs. tretinoin microsphere gel and adapalene gel. J Drugs Dermatol. 2009;8(4):383-8.

Callender VD, Young CM, kindred C, Taylor SC. Callender center for clinical research, Glenn Dale, Maryland; Society Hill Dermatology, Philadelphia, Pennsylvania, J Clin Aesthet Dermatol. 2012;5(7):25–32.

Callender VD. Acne in ethnic skin: special considerations for therapy. Dermatol Ther. 2004;17:184–195.

Lowe NJ, Rizk D, Grimes P, Billips M, Pincus S. Azelaic acid 20% cream in the treatment of facial hyperpigmentation in darker-skinned patients. Clin Ther. 1998;20:945–59.